NCT04822337 2026-04-16
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Active not recruiting
Clinical Trials
21 trialsNCT02420860 2026-04-15
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04978584 2026-04-15
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02203643 2026-04-14
FORTE
University of Turin, Italy
Phase 2 Completed
NCT03500445 2026-04-13
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
Phase 2 Active not recruiting
NCT01054196 2026-04-08
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT01241734 2026-04-08
RICER
Hackensack Meridian Health
Phase 1/2 Completed
NCT03993912 2026-04-07
IFM2017_03
University Hospital, Lille
Phase 3 Active not recruiting
NCT07030699 2026-04-07
ECLAT
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT00430365 2026-04-06
IFM2005-02
University Hospital, Toulouse
Phase 3 Completed
NCT01191060 2026-04-06
IFM/DFCI2009
University Hospital, Toulouse
Phase 3 Completed
NCT01723839 2026-04-03
FCR
Hackensack Meridian Health
Phase 2 Completed
NCT04876248 2026-03-31
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT06192888 2026-03-27
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT02446236 2026-03-24
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
Hackensack Meridian Health
Phase 1 Active not recruiting
NCT04268498 2026-03-24
ADVANCE
University of Miami
Phase 2 Active not recruiting
NCT06793189 2026-03-24
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Ruijin Hospital
Phase 2 Recruiting
NCT01297764 2026-03-23
QUAD
Hackensack Meridian Health
Phase 1/2 Active not recruiting
NCT02573896 2026-03-23
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
NCT05025800 2026-03-20
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT07485647 2026-03-20
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Vanderbilt-Ingram Cancer Center
Phase 2 Not yet recruiting